证券代码：002675 证券简称：东诚药业 公告编号：2024-058 烟台东诚药业集团股份有限公司 关于控股股东部分股权质押、展期及补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 截至公告披露日，控股股东东益生物及其一致行动人所持质押股份情况如下： 股东名 称 持股数量 （股） 持股比 例 累计质押 数量（股） 占其所 持股份 比例 占公司 总股本 比例 已质押股份情况 未质押股份情况 已质押股 份限售和 冻结数量 （股） 占已质 押股份 比例 未质押股 份限售和 冻结数量 （股） 占未质 押股份 比例 烟台东 益生物 工程有 限公司 124,888,049 15.15% 34,025,000 27.24% 4.13% 0 0 0 0 由守谊 103,305,678 12.53% 52,548,000 50.87% 6.37% 41,518,000 79.01% 35,961,258 70.85% 厦门鲁 鼎志诚 股权投 资管理 合伙企 业（有 限合 伙） 3,056,768 0.37% 0 0 0 0 0 0 0 合计 231,250,49 ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-057 烟台东诚药业集团股份有限公司 关于实际控制人部分股权质押展期及补充质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 烟台东诚药业集团股份有限公司（以下简称"公司"或"本公司"）于近日 收到公司实际控制人由守谊先生的通知，由守谊先生将其持有的本公司部分股权 进行质押展期及补充质押，具体情况如下： 根据《通知》所述，截至2024年9月5日由守谊先生持有东诚药业股票 103,305,678股，累计质押52,548,000股，累计质押股份占所持股份总数的50.87%， 股权质押风险总体可控，目前不存在平仓风险。 注：质押股份均为高管锁定股。 二、股东股份补充质押的情况 三、股东所持股份累计被质押的情况 截至公告披露日，实际控制人由守谊先生及其一致行动人所持质押股份情况 如下： | | | | | 占其所 | 占公 | 已质押股份情况 | | 未质押股份情况 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ...

Investment Rating - The investment rating for Dongcheng Pharmaceutical is maintained as "Buy" [4][7]. Core Insights - Dongcheng Pharmaceutical reported a revenue of 1.421 billion yuan for the first half of 2024, a year-on-year decrease of 20.41%, and a net profit attributable to shareholders of 112 million yuan, down 39.35% year-on-year [2][6]. - The nuclear medicine business remains stable, while revenue from heparin raw materials has declined significantly [6]. - The company has a robust product pipeline and production layout in the nuclear medicine sector, with multiple production centers operational and under construction [6]. Financial Performance - For the first half of 2024, the nuclear medicine segment generated revenue of 499 million yuan, a slight decrease of 0.58% year-on-year, while the heparin raw materials segment saw a revenue drop of 31.03% to 657 million yuan [6]. - The gross margin for the nuclear medicine business improved by 1.99 percentage points, while the heparin raw materials segment's gross margin increased by 1.23 percentage points despite the revenue decline [6]. - The forecasted revenues for 2024-2026 are 3.376 billion yuan, 3.628 billion yuan, and 3.869 billion yuan, with respective year-on-year growth rates of 3.08%, 7.46%, and 6.63% [7]. Business Outlook - The company is expected to maintain a leading position in the nuclear medicine market, with ongoing investments in production centers and a diverse range of products under development [6][7]. - The projected net profits for 2024-2026 are 314 million yuan, 366 million yuan, and 424 million yuan, with significant growth anticipated in 2024 at 49.69% year-on-year [7].

Group 1: Financial Performance - In the first half of 2024, the company achieved operating revenue of 1.421 billion yuan, a year-on-year decrease of 20.41% [2] - The net profit attributable to shareholders was 112 million yuan, down 39.35% year-on-year [2] - The sales revenue of the nuclear medicine segment was 499 million yuan, a decline of 0.58% [2] - Key product 18 F-FDG generated revenue of 195 million yuan, down 4.30% [2] - The iodine raw material drug segment reported sales of 657 million yuan, a decrease of 31.03% [2] - The sales revenue of the formulation segment was 179 million yuan, down 32.01% [2] Group 2: Product Development and Clinical Trials - The company is conducting Phase III clinical trials for 18 F-LNC1001 injection [2] - 18 F-LNC1005 injection has completed Phase I clinical trials [2] - 177 Lu-LNC1004 injection is undergoing clinical trials in China and Singapore [2] - 8 nuclear medicine production centers are currently under construction, with a total of 30 operational centers covering 93.5% of the domestic nuclear medicine demand [2]

Investment Rating - The investment rating for the company is "Strongly Recommended" [1][9] Core Views - The company's short-term performance is impacted by the decline in raw material drug sales, particularly heparin, but there is a strong long-term outlook for its nuclear medicine segment [4][5] - The company reported a revenue of 1.421 billion yuan for the first half of 2024, a decrease of 20.41%, and a net profit of 112 million yuan, down 39.35% [3][4] - The nuclear medicine segment maintained stability with a revenue of 499 million yuan, while the raw material drug segment saw a significant decline in revenue [4][5] Financial Performance Summary - The company achieved a revenue of 1.421 billion yuan in H1 2024, down 20.41%, with a net profit of 112 million yuan, down 39.35% [3] - In Q2 2024, the company reported a revenue of 773 million yuan, a decrease of 17.23%, and a net profit of 47 million yuan, down 64.63% [3] - The raw material drug segment's revenue was 657 million yuan, down 31.03%, with heparin revenue specifically declining by 39.02% [4] Research and Development - The company increased its R&D investment to 165 million yuan in H1 2024, with a R&D expense ratio of 6.40% [4] - The company has multiple promising products in its pipeline, including the recently approved technetium-99m injection [4][5] Market Outlook - The nuclear medicine industry is expected to continue its upward trend, with the company positioned to benefit from its expanding pipeline and operational nuclear pharmacies [5][6] - The average export price of heparin has stabilized, suggesting limited downside risk and potential for price recovery [4][5]

公司法定代表人：由守谊 主管会计工作负责人：朱春萍 会计机构负责人：王超 烟台东诚药业集团股份有限公司2024半年度非经营性资金占用及其他关联资金往来情况汇总表 | 编制单位：烟台东诚药业集团股份有限公司 | | | | | | | | | 单位：人民币万元 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金 占用 | 资金占用方名称 | 占用方与上市公司的关联关系 | 上市公司核算 的会计科目 | 2024 年期初占用 资金余额 | 2024 年 1-6 月占 用累计发生金额 | 2024 年 1-6 月 占用资金的利 | 2024 年 1-6 月 偿还累计发生 | 2024 年 6 月 30 日占用资金余额 | 占用形成原因 | 占用性质 | | | | | | | （不含利息） | 息（如有） | 金额 | | | | | 控股股东、实 | | | | | | | | | | | | 际控制人及其 | | | | | | | | | | 非经营性占用 | | 附属企业 | | | | | | | ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-055 烟台东诚药业集团股份有限公司关于 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求（2022 年修订）》（证监会公告[2022]15 号）、深 圳证券交易所发布的《深圳证券交易所上市公司自律监管指引第 1 号——主板上 市公司规范运作（2023 年 12 月修订）》（深证上〔2023〕1145 号）及《深圳证 券交易所上市公司自律监管指南第 2 号——公告格式（2024 年修订）》（深证 上〔2024〕399 号）等有关规定，烟台东诚药业集团股份有限公司（以下简称"公 司"或"本公司"）董事会编制了 2024 年半年度募集资金存放与实际使用情况 专项报告。 一、 募集资金基本情况 1、实际募集配套资金金额和资金到账时间 根据中国证券监督管理委员会《关于核准烟台东诚药业集团股份有限公司向 由守谊发行股份购买资产并募集配套资金的批复》（"证监许可【 ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-056 内容详见刊载于《证券时报》、《证券日报》、《中国证券报》、《上海证券 报》和巨潮资讯网（www.cninfo.com.cn）《2024年半年度报告摘要》及刊载于巨潮 资讯网（www.cninfo.com.cn）《2024年半年度报告全文》。 表决情况：同意 3 票，反对 0 票，弃权 0 票。 烟台东诚药业集团股份有限公司 第六届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2024 年 8 月 30 日，烟台东诚药业集团股份有限公司（以下简称"公司"）第六 届监事会第三次会议在山东省烟台经济技术开发区长白山路 7 号公司会议室召开。 会议通知于 2024 年 8 月 20 日以通讯方式发送至全体监事。本次会议由监事会主席 柳青林先生主持，应出席监事 3 人，实出席监事 3 人，董事会秘书刘晓杰先生列席， 符合法律法规及公司章程的有关规定。 二、监事会会议审议情况 （一）审议通过《2024 年半年度报告及其摘要》 经审核，监事会认为：董事 ...

证券代码：002675 证券简称：东诚药业 公告编号：2024-052 烟台东诚药业集团股份有限公司 第六届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 2024 年 8 月 30 日，烟台东诚药业集团股份有限公司（以下简称"东诚药业" 或"公司"）在山东省烟台经济技术开发区长白山路 7 号公司会议室召开了第六届 董事会第五次会议。会议通知于 2024 年 8 月 20 日以通讯方式送达。会议采用现 场结合通讯方式召开，会议应到董事 5 人，实到董事 5 人。公司全体监事和高级 管理人员列席了本次会议。会议由公司董事长由守谊先生主持，会议召开符合《中 华人民共和国公司法》（以下简称"《公司法》"）及《烟台东诚药业集团股份有限 公司章程》（以下简称"《公司章程》"）等有关规定。 二、董事会会议审议情况 全体董事经过审议，以记名投票表决方式表决通过了如下议案： （一）审议通过《2024 年半年度报告及其摘要》 表决情况：同意 5 票，反对 0 票，弃权 0 票。 三、备查文件 1、经与会董事签字并加盖董事会印章的 ...

Financial Performance - Revenue for the reporting period was RMB 1.42 billion, a decrease of 20.41% compared to the same period last year[10] - Net profit attributable to shareholders of the listed company was RMB 111.79 million, a decrease of 39.35% year-on-year[10] - Net cash flow from operating activities was negative RMB 17.79 million, a significant decrease of 245.45% compared to the same period last year[10] - Basic earnings per share (EPS) was RMB 0.1356, down 39.33% year-on-year[10] - Total assets increased by 7.26% to RMB 8.67 billion compared to the end of the previous year[10] - Shareholders' equity decreased by 7.02% to RMB 4.44 billion compared to the end of the previous year[10] - The weighted average return on equity (ROE) was 2.33%, down 1.48 percentage points from the same period last year[10] - Revenue for the first half of 2024 was 1.421 billion yuan, a year-on-year decrease of 20.41%[15] - Net profit attributable to shareholders was 112 million yuan, a year-on-year decrease of 39.35%[15] - Revenue for the first half of 2024 decreased to 651,973,024.64 RMB, a significant drop from 926,651,055.45 RMB in the same period of 2023[112] - Net profit for the first half of 2024 was 68,909,543.50 RMB, compared to 160,804,051.67 RMB in the first half of 2023[112] - Operating cash flow for the first half of 2024 was negative at -17,786,859.20 RMB, a sharp decline from 12,228,463.70 RMB in the same period of 2023[114] - Sales revenue from goods and services in the first half of 2024 was 1,351,467,618.40 RMB, down from 1,877,162,768.94 RMB in the first half of 2023[114] - R&D expenses for the first half of 2024 were 20,127,405.08 RMB, a decrease from 26,333,874.80 RMB in the same period of 2023[112] - Interest income for the first half of 2024 was 7,662,506.26 RMB, slightly lower than 8,214,946.61 RMB in the first half of 2023[112] - Tax refunds received in the first half of 2024 were 49,417,487.10 RMB, down from 90,094,193.62 RMB in the same period of 2023[114] - Total comprehensive income for the first half of 2024 was 68,909,543.50 RMB, compared to 160,804,051.67 RMB in the first half of 2023[113] - Operating profit for the first half of 2024 was 82,255,458.94 RMB, a significant decrease from 182,749,108.33 RMB in the same period of 2023[112] - Investment losses for the first half of 2024 were -11,418,356.07 RMB, compared to a gain of 33,397,972.72 RMB in the first half of 2023[112] - Investment activities generated a net cash outflow of -481,241,778.83 yuan, compared to -247,378,033.30 yuan in the same period last year[115] - Financing activities generated a net cash inflow of 732,078,839.85 yuan, a significant increase from 109,794,678.94 yuan in the same period last year[115] - Cash and cash equivalents increased by 239,940,949.57 yuan, compared to a decrease of -123,558,257.08 yuan in the same period last year[115] - Sales revenue from goods and services was 556,657,607.02 yuan, a decrease from 934,866,051.98 yuan in the same period last year[115] - Investment income received was 4,025,196.95 yuan, a sharp decline from 50,893,205.53 yuan in the same period last year[115] - The company received 687,988,680.00 yuan from absorbing investments, a significant increase from 51,500,000.00 yuan in the same period last year[115] - The company repaid 474,119,112.54 yuan in debt, compared to 217,000,012.10 yuan in the same period last year[115] - The company's cash and cash equivalents at the end of the period were 847,679,131.19 yuan, compared to 803,292,557.04 yuan in the same period last year[115] - The company's total owner's equity at the end of the period was 5,395,623,912.68 yuan[117] - The company's net cash outflow from investment activities was -90,588,059.40 yuan, compared to a net inflow of 32,107,435.00 yuan in the same period last year[116] - The company's comprehensive income for the first half of 2024 was RMB 104.98 million, with a total comprehensive income of RMB 113.12 million[118] - The company's total equity at the end of the period was RMB 5.42 billion, an increase of RMB 149.27 million compared to the beginning of the period[121] - The company's net profit attributable to shareholders was RMB 181.80 million, a decrease of RMB 2.51 million compared to the same period last year[121] - The company's capital reserve increased by RMB 40.10 million during the period, reaching RMB 2.44 billion at the end of the period[122] - The company's undistributed profit at the end of the period was RMB 1.36 billion, an increase of RMB 560.62 million compared to the beginning of the period[121] - The company's total assets at the end of the period were RMB 8.25 billion, with total liabilities of RMB 2.84 billion[118] - The company's operating income for the first half of 2024 was RMB 2.34 billion, a decrease of RMB 337.31 million compared to the same period last year[118] - The company's minority shareholders' equity at the end of the period was RMB 584.74 million, an increase of RMB 51.07 million compared to the beginning of the period[122] - The company's total comprehensive income for the first half of 2024 was RMB 113.12 million, with a net profit attributable to shareholders of RMB 104.98 million[118] - The company's total equity at the end of the period was RMB 5.42 billion, with a total comprehensive income of RMB 113.12 million for the first half of 2024[121] Business Segments and Products - The company's products include heparin, low molecular weight heparin, chondroitin sulfate, and chondroitin sulfate sodium[4] - The company's subsidiaries are involved in nuclear medicine and biotechnology, such as Dongcheng Nuclear Medicine and Yantai Mindo[4] - The company's products are subject to GMP standards and NMPA regulations[4] - Nuclear medicine business revenue was 499 million yuan, a year-on-year decrease of 0.58%, with key product 18F-FDG revenue at 195 million yuan, down 4.30%[15] - API business revenue was 657 million yuan, a year-on-year decrease of 31.03%, with heparin API revenue at 483 million yuan, down 39.02%[15] - Formulation business revenue was 179 million yuan, a year-on-year decrease of 32.01%, with key product hydrocortisone sodium succinate injection revenue at 57.16 million yuan, down 22.38%[15] - The company received approval for Technetium [⁹⁹ᵐTc] Tektrotyd Injection, enhancing its product line and market competitiveness[16] - Mido Biotech has assisted in obtaining clinical trial approvals for over 20 nuclear medicine products and provides comprehensive CRO and CDMO services[17] - The company operates a global sales network across 40+ countries and regions, specializing in heparin API and chondroitin sulfate[18] - Heparin sodium API can be directly used to produce ordinary heparin preparations or low molecular weight heparin sodium API, which is widely used in clinical anticoagulation therapy[19] - Chondroitin sulfate is divided into pharmaceutical-grade and food-grade, with pharmaceutical-grade used for treating osteoarthritis, hyperlipidemia, and other diseases, while food-grade is used in health foods and beverages[19] - The company's nuclear medicine products adopt a production model based on sales orders, with long half-life products combining inventory and market conditions, while short half-life products use customized production[20] - The company's API products are sold through a mixed model of direct sales and distributor sales, with a sales network covering nearly 40 countries and regions[21] - The company's preparation business adopts a marketing model combining centralized procurement participation and agent promotion, with a focus on academic promotion and brand awareness[22] - The company's performance is driven by national policies promoting nuclear medicine development, including inclusion in the national medical insurance catalog and large medical equipment configuration plans[23] - The company has established a high-tech barrier nuclear medicine ecosystem network, forming a complete industrial chain from raw material supply to sales, with core competitiveness in product layout, production network layout, and innovative R&D[27] - The company has 30 operational nuclear medicine production centers, covering 93.5% of the domestic population's nuclear medicine needs, with 8 additional centers under construction[29] - The company's R&D platform, Yantai Lannacheng, focuses on radioactive diagnostic and therapeutic drugs, with multiple products in clinical trials, including 18F-Sirituximab in Phase III and 177Lu-LNC1004 in Phase I in China and Singapore[26] - The company has a diversified product line in nuclear medicine, covering diagnosis and treatment for cancer, neurodegenerative diseases, and cardiovascular diseases, with products like 18F-FDG, 99mTc-labeled drugs, and 131I-sodium iodide oral solution[28] - The company has a vertical integration advantage in the pharmaceutical industry, from raw materials to finished products, enhancing cost efficiency and market competitiveness[30] - The company is a global leader in heparin API production, with certifications from FDA, EDQM, and PMDA, and exports to over 40 countries[31] - The company has established a strong brand in the anticoagulant market, with a diverse product portfolio including nadroparin calcium and enoxaparin sodium injections[33] - The company has been recognized as one of the top 100 innovative enterprises in Shandong and ranked 47th in the 2023 China Chemical Pharmaceutical Enterprises Top 100 by MiNet[34] - The company operates in three main business segments: API (Active Pharmaceutical Ingredient), formulations, and nuclear medicine, with a global sales network spanning over 40 countries and regions[131] - The API segment is a leading global supplier of heparin API and chondroitin sulfate (both pharmaceutical and dietary supplement grades)[131] - The formulations segment includes a production capacity of 30 million freeze-dried powder injections annually, covering therapeutic areas such as anticoagulation, cardiovascular, oncology, urology, orthopedics, and anti-infectives[131] - The nuclear medicine segment focuses on building a full industry chain from diagnostic to therapeutic nuclear drugs, emphasizing integrated diagnosis and treatment and precision medicine[131] Subsidiaries and Investments - The company's subsidiaries include Dongcheng Northern, Dongcheng Ocean, Dongyuan Bio, Dongcheng Hong Kong, Yunkang Pharmaceutical, and Andike[4] - The company's subsidiaries operate in various regions, including Hong Kong, Nanjing, and Yantai[4] - The company's investment in Zhongtai Biological Products Co., Ltd. (70% equity) generated a net profit of 14,178,900 yuan in the reporting period[45] - The company invested RMB 20,000,000 in Qikang Yuan Medical Technology (Changzhou) Co., Ltd., acquiring a 50% stake[51] - The subsidiary Chengdu Yunke Pharmaceutical Co., Ltd. reported a net profit of RMB 57.04 million, with total assets of RMB 813.58 million and revenue of RMB 145.88 million[57] - Shanghai Xinke Pharmaceutical Co., Ltd. achieved a net profit of RMB 21.66 million, with total assets of RMB 155.59 million and revenue of RMB 103.01 million[57] - Nanjing Jiangyuan Andikezheng, another subsidiary, recorded a net profit of RMB 46.15 million, with total assets of RMB 1.59 billion and revenue of RMB 169.23 million[57] - Yantai Dongcheng Northern Pharmaceutical Co., Ltd. reported a net profit of RMB 10.85 million, with total assets of RMB 488.21 million and revenue of RMB 146.28 million[58] - Sino Siam Biotechnique Co., Ltd. achieved a net profit of RMB 14.18 million, with total assets of RMB 198.50 million and revenue of RMB 48.19 million[58] - Yantai Lannacheng Biotechnology Co., Ltd. reported a net loss of RMB 46.18 million, with total assets of RMB 416.08 million and no revenue[58] - Aprinoia Therapeutics Inc., a joint venture, recorded a net loss of RMB 61.96 million, with total assets of RMB 29.84 million and revenue of RMB 3.56 million[58] - The company's subsidiary YANTAI LNC BIOTECHNOLOGY SINGAPORE PTE.LTD. received FDA approval for clinical trials of 68 Ga-LNC1007 injection[87] - The company's subsidiary Lanacheng acquired the rights to the lung cancer imaging diagnostic nuclear medicine product for RMB 63 million[87] - The company's subsidiary Yitai Pharmaceutical acquired the rights to the liver function testing diagnostic nuclear medicine product for RMB 85 million[87] - The company's subsidiary Yantai Mido raised RMB 380 million through a capital increase from 7 investors[88] - The company's wholly-owned subsidiary subscribed to USD 4 million in convertible bonds of XING2DIAGNOSTICS, INC, accounting for 61.54% of the issuance[88] - The company's subsidiary LNC PHARMA PTE. LTD. received clinical trial authorization for 68 Ga-LNC1007 injection in Singapore[88] - The company's subsidiary Lanacheng raised RMB 300 million through a capital increase from 9 investors[88] - The company's subsidiary Lanacheng received clinical trial approval for 177 Lu-LNC1008 injection from the NMPA[88] - The company's subsidiary LNC PHARMA PTE. LTD. received FDA approval for clinical trials of 18 F-LNC1007 injection in Australia[88] - The new Hefei nuclear medicine production center of the wholly-owned subsidiary Andike has been put into operation, expanding the company's production capacity[89] - The subsidiary LNC PHARMA PTE. LTD. received FDA approval for the clinical trial of 177 Lu-LNC1011 injection[89] - The wholly-owned subsidiary Andike obtained the NMPA approval for the production and sales of Technetium [99m Tc] Tetrofosmin Injection[89] - The holding subsidiary Yantai Lannacheng received NMPA approval for the clinical trial of 177 Lu-LNC1011 injection[89] Risks and Challenges - The company faces risks including raw material procurement, product quality, sales price fluctuations, production safety, and talent shortages[1] - The company faces risks from raw material price fluctuations, particularly due to the impact of African swine fever on heparin crude prices[60] - Increased depreciation from high fixed asset investments may lead to a decline in performance, especially during the initial phase of new projects[60] - The company is exposed to environmental and safety risks, with potential increases in compliance costs due to stricter regulations[60] - The company's future development statements are considered planning items and do not constitute substantive commitments to investors[1] Environmental and Safety Compliance - The company's wastewater treatment facilities use a combination of hydrolysis acidification, anaerobic, and aerobic processes, ensuring stable emission concentrations with online monitoring equipment installed at discharge points[67] - The company's exhaust gas treatment facilities primarily use spray absorption and activated carbon methods to pre-treat volatile organic compounds, ensuring emissions meet national and regional standards[67] - The company's actual environmental protection tax payment for the first half of 2024 was 25,643.28 yuan, benefiting from a 50% reduction due to pollutant concentrations being below 50% of the standard limits[70] - The company's wastewater discharge permit allows a daily discharge volume of 400m³, with pollutants meeting the GB/T31962-2015 standard[71] - The company's environmental credit rating for 2024 is classified as "Green Label" according to the Shandong Province Enterprise Environmental Credit Evaluation[71] - The company has successfully passed ISO14001 and ISO45001 system audits, emphasizing energy conservation, pollution prevention, and safety[69] - The company has implemented an environmental emergency response plan, including regular drills and detailed environmental risk management measures[69] - The company's wastewater discharge at the main plant site includes COD at 28.8mg/L, ammonia nitrogen at 2.09mg/L, and total nitrogen at 25.7mg/L, all within permitted limits[66] - The company's volatile organic compound emissions are at 29.45mg/m³, well below the permitted limit of 15.734 tons[66] - The company has no record of environmental penalties during the reporting period, indicating compliance with environmental regulations[71] - The company's environmental credit rating for 2024 is Green Label, indicating compliance with environmental standards[72] Corporate Governance and Compliance - The company's financial reports are signed by the legal representative, financial officer, and accounting officer, ensuring accuracy and completeness[3] - The company's financial reports and disclosed documents are available at the company's securities department[3] - The company has no significant legal disputes, penalties, or bankruptcy-related issues during the reporting period[74][75][76] - No non-operational fund occupation by controlling shareholders or related parties was reported[74] - The company provided guarantees totaling 90,000 million yuan for subsidiaries, with actual guarantees issued amounting to 7,419 million yuan[83] - The total actual guarantee balance for subsidiaries at the end of the reporting period was 9,789 million yuan, accounting for 2.56% of the company's net assets[83] - The company engaged in bank wealth management products with a total investment of 31,329.5 million yuan, of which 10,900 million yuan remains outstanding[84] - No significant related-party